Trial Profile
Subcutaneous Immunoglobulin Replacement Therapy in Patients with Primary Immunodeficiency in Routine Clinical Practice: The VISPO Prospective Multicenter Study.
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Nov 2019
Price :
$35
*
At a glance
- Drugs Immune globulin (Primary)
- Indications Immunodeficiency disorders
- Focus Pharmacokinetics; Therapeutic Use
- Acronyms VISPO
- 28 Oct 2015 New trial record